Apnimed advances oral OSA therapy case as AD109 heads toward FDA decision window
Find out how Apnimed’s AD109 Phase 3 data could reshape oral treatment for obstructive sleep apnea as FDA review approaches.
LivaNova PLC expands sleep apnea eligibility as aura6000 gains FDA approval without CCC limits
LivaNova PLC secures FDA approval for aura6000. Discover how it could reshape sleep apnea treatment and expand patient eligibility.